Cybin: CYB003 Achieves ‘Primary Efficacy Endpoint’ in Phase 2 Study

December 1, 2023

Cybin to Release Phase 2 Data for CYB003 Psilocybin Treatment in Live Webcast

November 28, 2023

Cybin Raises $30 Million Through Underwritten Offering

November 16, 2023

Cybin Psilocybin Phase 2 Trial Shows Significant Reduction in Depressive Symptoms

November 3, 2023